ProfileGDS5678 / 1441952_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 73% 78% 73% 71% 81% 78% 73% 74% 74% 73% 73% 73% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1199976
GSM967853U87-EV human glioblastoma xenograft - Control 24.718573
GSM967854U87-EV human glioblastoma xenograft - Control 35.4061878
GSM967855U87-EV human glioblastoma xenograft - Control 44.7874173
GSM967856U87-EV human glioblastoma xenograft - Control 54.4764171
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6171181
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2176878
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6857873
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8061774
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8688574
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6411773
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7668773
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7356473
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8737575